

Disclosing changes in the company's administrative structure at the level of executive management

Date	17 th August 2026
Name of the Listed Company	Gulf Pharmaceutical Industries - JULPHAR
The name of the persons appointed	1) Faisal Fahad Al Tlasi, General Manager – Saudi Arabia 2) Khaled Tawfik Mohamed Khalil- Chief Commercial Officer
Starting date of appointment / assignment	17 th August 2026
A brief summary of the CV for the appointed persons	Faisal Al Tlasi:- Faisal is a senior pharmaceutical industry executive with over 25 years of leadership experience in Saudi Arabia, specializing in commercial strategy, business transformation, P&L management, and organizational growth. He has held senior leadership positions at Axantia Group, Sudair Pharmaceutical Company, and Hikma Pharmaceuticals, where he successfully drove revenue expansion, market access, operational excellence, and commercial performance. Faisal also contributes to the development of Saudi Arabia's pharmaceutical sector through his involvement with the National Committee for Pharmaceutical Industries under the Council of Saudi Chambers. Khaled Khalil:- Khaled is a seasoned pharmaceutical executive with over 30 years of commercial leadership experience across the GCC, Middle East, Africa, Turkey, and Pakistan. He has held senior leadership positions with leading multinational healthcare companies, including Abbott Nutrition, GlaxoSmithKline, Eli Lilly, and most recently Pharco Pharmaceuticals. Khalid brings extensive expertise in commercial strategy, P&L management, business transformation, market expansion, and leading multi-country operations, with a proven track record of delivering sustainable growth and building high-performing organizations.

The Name of the Authorized Signatory	Basel Ziyadeh
Designation	Chief Executive Officer
Signature and Date	17 th August 2026